Copyright
©The Author(s) 2025.
World J Clin Oncol. Jun 24, 2025; 16(6): 105601
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.105601
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.105601
Table 1 T classification in tumor-node-metastasis system for pancreatic ductal adenocarcinoma of American Joint Committee on Cancer 8th edition
T | Greatest dimension (cm) |
Tis | In situ |
T1 | ≤ 2 |
T1a | ≤ 0.5 |
T1b | > 0.5 and < 1 |
T1c | 1-2 |
T2 | > 2 and ≤ 4 |
T3 | > 4 |
T4 | Involvement of celiac axis, superior mesenteric artery, and/or common hepatic artery |
Table 2 Tumor-node-metastasis staging for pancreatic ductal adenocarcinoma of American Joint Committee on Cancer 8th edition
Stage | Parameters |
0 | Tis, N0, M0 |
I | |
Ia | T1, N0, M0 |
Ib | T2, N0, M0 |
II | |
IIa | T3, N0, M0 |
IIb | T1-T3, N1, M0 |
III | Any T, N2, M0 or T4, any N, M0 |
IV | Any T, any N, M1 |
Table 3 Predictive factors for favorable prognosis of pancreatic ductal adenocarcinoma
Number | Factor |
1 | Stage T1-T2 |
2 | Without metastases beyond the pancreas |
3 | Curative surgical resection |
4 | R0 resection without infiltration of resection margins |
5 | G1 (high) cell differentiation or even G2 (moderate); G3 (poor) provides worse outcomes |
6 | Absence of lymph node infiltration |
7 | Retrieved lymph nodes > 12 |
8 | Absence of perineural invasion |
9 | Neoadjuvant systemic treatment in borderline resectable cases, at least |
10 | Novel adjuvant systemic treatment |
11 | Absence of early recurrence |
12 | Without malnutrition and sarcopenia |
13 | Multimodality treatment |
- Citation: Pavlidis ET, Galanis IN, Pavlidis TE. Updates in the diagnosis and management of ductal adenocarcinoma of the pancreas. World J Clin Oncol 2025; 16(6): 105601
- URL: https://www.wjgnet.com/2218-4333/full/v16/i6/105601.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i6.105601